New drug combo aims to control tough leukemia

NCT ID NCT06308588

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The trial enrolls 40 adults who are not good candidates for strong chemotherapy. Researchers will monitor safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blinatumomab and asciminib
What this could lead to: If it works, this combination could offer a new treatment option for people with Ph-positive ALL who cannot tolerate intensive chemotherapy.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply to everyone. Side effects from the drug combination are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive leukemia, acute lymphocytic, susceptibility to, 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA PHILADELPHIA CHROMOSOME POSITIVE

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Montefiore Einstein Comprehensive Cancer Center
NOT_YET_RECRUITING

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.